A DNA Methylation-Based Panel for the Prognosis and Dagnosis of Patients With Breast Cancer and Its Mechanisms

Xiao-Ping Liu 1, Jinxuan Hou 2, Chen Chen 3 4, Li Guan 3 4, Han-Kun Hu 5, Sheng Li 3 4

Affiliations

PMID: 32733914
PMCID: PMC7358612
DOI: 10.3389/fmolb.2020.00118

Free PMC article

Abstract

Objective: To identify DNA methylation related biomarkers in patients with breast cancer (BC).

Materials and methods: A total of seven BC methylation studies including 1,438 BC patients or breast tissues were included in this study. An elastic net regularized Cox proportional hazards regression (CPH) model was used to build a multi-5'-C-phosphate-G-3' methylation panel. The diagnosis and prognosis power of the panel was evaluated and validated using a Kaplan-Meier curve, univariate and multivariable CPH, subgroup analysis. A nomogram containing the panel was developed. The relationships between the panel-based methylation risk and the immune landscape and genomic metrics were investigated.

Results: Sixty-eight CpG sites were significantly correlated with the overall survival (OS) of BC patients, and based on the result of penalized CPH, a 28-CpG site based multi CpG methylation panel was found. The prognosis and diagnosis role of the panel was validated in the discovery set, validation set, and six independent cohorts, which indicated that higher methylation risk was associated with poor OS, and the panel outperformed currently available biomarkers and remained an independent factor after adjusting for other clinical features. The methylation risk was negatively correlated with innated and adaptive immune cells, and positively correlated with total mutation load, SCNA, and MATH.

Conclusions: We validated a multi CpG methylation panel that could independently predict the OS of BC patients. The Th2-mediated tumor promotion effect-suppression of innate and adaptive immunity-participated in the progression of high-risk BC. Patients with high methylation risk were associated with tumor heterogeneity and poor survival.

Keywords: DNA methylation; breast cancer; diagnosis; genomic metrics; immune landscape; prognosis.